130 related articles for article (PubMed ID: 37992586)
1. Drug-drug interaction between paxlovid and tacrolimus in a patient with myasthenia gravis and SARS-CoV-2 infection.
Chen Y; Wan W; Yao X; Guan Y
J Neuroimmunol; 2023 Dec; 385():578245. PubMed ID: 37992586
[TBL] [Abstract][Full Text] [Related]
2. Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report.
Prikis M; Cameron A
Transplant Proc; 2022; 54(6):1557-1560. PubMed ID: 35599203
[TBL] [Abstract][Full Text] [Related]
3. Myasthenia Gravis Complicated with Peripheral T-cell Lymphoma, Not Otherwise Specified (PTCL-NOS), Following Thymectomy and Longstanding Tacrolimus Therapy.
Ohara M; Ozaki K; Ohkubo T; Yamada A; Numasawa Y; Tanaka K; Tomii S; Ishibashi S; Sanjo N; Yokota T
Intern Med; 2018 Feb; 57(4):601-604. PubMed ID: 29269644
[TBL] [Abstract][Full Text] [Related]
4. New-onset Myasthenia Gravis after SARS-CoV-2 infection: case report and literature review.
Tereshko Y; Gigli GL; Pez S; De Pellegrin A; Valente M
J Neurol; 2023 Feb; 270(2):601-609. PubMed ID: 36352330
[TBL] [Abstract][Full Text] [Related]
5. Paxlovid-tacrolimus drug-drug interaction caused severe diarrhea that induced combined diabetic ketoacidosis and a hyperglycemic hyperosmolar state in a kidney transplant patient: a case report.
Luo W; He Y; Wei MG; Lu GB; Yi Q
J Med Case Rep; 2023 Sep; 17(1):406. PubMed ID: 37742028
[TBL] [Abstract][Full Text] [Related]
6. Case report: Supratherapeutic tacrolimus concentrations with nirmatrelvir/ritonavir in a lung transplant patient: a case report using Rifampin for reversal.
Xiong Y; Wang X; Li S; Zhang Q; Guo L; Chen W; Zhao Z; Liu L
Front Pharmacol; 2023; 14():1285078. PubMed ID: 38026995
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis.
Wakata N; Saito T; Tanaka S; Hirano T; Oka K
Clin Neurol Neurosurg; 2003 Dec; 106(1):5-8. PubMed ID: 14643908
[TBL] [Abstract][Full Text] [Related]
8. Case series of COVID-19 in patients with myasthenia gravis: a single institution experience.
Županić S; Perić Šitum M; Majdak M; Karakaš M; Bašić S; Sporiš D
Acta Neurol Belg; 2021 Aug; 121(4):1039-1044. PubMed ID: 33797054
[TBL] [Abstract][Full Text] [Related]
9. Dose optimization of tacrolimus with therapeutic drug monitoring and CYP3A5 polymorphism in patients with myasthenia gravis.
Chen D; Hou S; Zhao M; Sun X; Zhang H; Yang L
Eur J Neurol; 2018 Aug; 25(8):1049-e80. PubMed ID: 29611886
[TBL] [Abstract][Full Text] [Related]
10. Safety and Immunogenicity of Additional SARS-CoV-2 Vaccinations in a Patient With Myasthenia Gravis on Mycophenolate: A Case Report.
McNeish BL; Colletti RB; Hehir MK
J Clin Neuromuscul Dis; 2022 Dec; 24(2):113-114. PubMed ID: 36409346
[No Abstract] [Full Text] [Related]
11. Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis.
Kim YH; Shin HY; Kim SM
Yonsei Med J; 2019 Jul; 60(7):633-639. PubMed ID: 31250577
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 in Refractory Myasthenia Gravis- A Case Report of Successful Outcome.
Ramaswamy SB; Govindarajan R
J Neuromuscul Dis; 2020; 7(3):361-364. PubMed ID: 32508329
[TBL] [Abstract][Full Text] [Related]
13. [A child with generalized myasthenia gravis successfully treated with tacrolimus].
Goto T; Mori M; Yamagata T; Mizuguchi M; Momoi MY
No To Hattatsu; 2007 Jul; 39(4):300-3. PubMed ID: 17633089
[TBL] [Abstract][Full Text] [Related]
14. Experience with starting tacrolimus postoperatively after transsternal extended thymectomy in patients with myasthenia gravis.
Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Gamez J; Armengol M
Curr Med Res Opin; 2006 May; 22(5):885-95. PubMed ID: 16709310
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and side effects of low-dose tacrolimus for the treatment of Myasthenia Gravis.
Tao X; Wang W; Jing F; Wang Z; Chen Y; Wei D; Huang X
Neurol Sci; 2017 Feb; 38(2):325-330. PubMed ID: 27873026
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis.
Wang L; Xi J; Zhang S; Wu H; Zhou L; Lu J; Zhang T; Zhao C
J Clin Neurosci; 2019 May; 63():160-167. PubMed ID: 30827886
[TBL] [Abstract][Full Text] [Related]
17. Low-dose tacrolimus for two cases of myasthenia gravis with invasive thymoma that relapsed shortly after thymectomy.
Tsukaguchi M; Shimamura M; Ikeda K; Urai Y; Sasaki I; Deguchi K; Touge T; Takeuchi H; Kuriyama S
J Neurol Sci; 2005 Apr; 231(1-2):85-8. PubMed ID: 15792826
[TBL] [Abstract][Full Text] [Related]
18. A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis.
Ahn SW; Joo IS; Kim BJ; Sung JJ; Kang SY; Oh J; Minn YK; Suh BC; Oh SY; Hong YH; Nam TS; Seok JI; Park YE; Shin HY; Cho EB; Shin JY; Seok HY; Park JS; Min JH; Seok JM; Kim BJ
J Neurol Sci; 2017 Aug; 379():271-275. PubMed ID: 28716258
[TBL] [Abstract][Full Text] [Related]
19. Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant.
Young C; Papiro T; Greenberg JH
Pediatr Nephrol; 2023 Apr; 38(4):1387-1388. PubMed ID: 35982345
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic efficacy and safety of tacrolimus for intractable myasthenia gravis: a report of 36 patients].
Feng HY; Liu WB; Qiu L; Huang X; Huang RX
Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(45):3190-2. PubMed ID: 22333101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
